Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-101 in moderate atopic dermatitis
NCT03859986Phase 2Unknown
- Sponsor
- Ralexar Therapeutics
- Start
- Mar 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rovazolac in atopic dermatitis (AD), sponsored by Ralexar Therapeutics. Status: unknown.
02
Drugs
rovazolac
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03859986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859986.